Skip to main content

How Accurate is Screening for Nasopharyngeal Carcinoma?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Sep 4, 2023.

Official answer

by Drugs.com

Clinical trial results for screening of nasopharyngeal cancer have shown a significant improvement in diagnosing accuracy for nasopharyngeal carcinoma. Trial results reported in the New England Journal of Medicine showed the novel biomarker P85-Ab, derived from Epstein-Barr virus (EBV) improved diagnostic performance in sensitivity, specificity, and positive predictive value compared to the standard two-antibody test.
Results from screening for nasopharyngeal cancer comparing the novel biomarker P85-Ab to the standard two-antibody–based screening method.

  • sensitivity (97.9% vs 72.3%)
  • specificity (98.3% vs 97.0%)
  • positive predictive value (PPV; 10.0% vs 4.3%).

The standard two-antibody–based screening method was EBV nuclear antigen 1 [EBNA1]–IgA and EBV-specific viral capsid antigen [VCA]–IgA.

Biomarker P85-Ab's high positive predictive value may improve the cost-effectiveness, capacity, and acceptance of nasopharyngeal carcinoma screening. Combining P85-Ab together with one or both of the standard antibodies would increase the positive predictive value further.

Nasopharyngeal carcinoma

Nasopharyngeal carcinoma is closely associated with the Epstein–Barr virus (EBV) which is classified as a group I carcinogen. The development of nasopharyngeal carcinoma is also influenced by genetic predisposition, and environmental factors including tobacco smoking, dietary components, and occupational exposure. Nasopharyngeal carcinoma (NPC) and gastric carcinoma accounted for 82% of EBV-attributed malignancies.

References

Anti–Epstein–Barr Virus BNLF2b for Mass Screening for Nasopharyngeal Cancer [Accessed September 4, 2023] https://www.nejm.org/doi/full/10.1056/NEJMoa2301496

The role of Epstein–Barr virus in nasopharyngeal carcinoma [Accessed September 4, 2023] https://www.frontiersin.org/articles/10.3389/fmicb.2023.1116143/full#:~:text=Nasopharyngeal%20carcinoma%20(NPC)%20is%20a,ethnic%20groups%20and%20endemic%20regions

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options [Accessed September 4, 2023] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480178/

Read next

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

What is the MOA of Loqtorzi (toripalimab)?

Loqtorzi (toripalimab) is a programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 protein on T-cells (a type of immune cell). It works by blocking PD-L1 and PD-L2 molecules found on the surface of some cancer cells. This allows the immune system to activate and kill the tumor. Loqtorzi is the first FDA-approved agent for nasopharyngeal carcinoma (NPC). Continue reading

How does Loqtorzi work for nasopharyngeal carcinoma?

Loqtorzi (toripalimab-tpzi) is a programmed death receptor-1 (PD-1) blocking antibody that works by binding to the PD-1 receptor that exists on the outside of some cancer cells. PD-1 prevents our immune system from attacking the cancerous cells, but once Loqtorzi has bound to PD-1, the immune system is no longer inhibited, and immune system components, such as T cells, can kill the cell. Continue reading

Related medical questions

Drug information

Related support groups